SAN.PA : Summary for SANOFI - Yahoo Finance

U.S. Markets open in 4 hrs 22 mins

Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
82.83+0.06 (+0.07%)
As of 9:52AM CET. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close82.77
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range82.53 - 82.96
52 Week Range62.50 - 83.73
Avg. Volume2,219,268
Market Cap104.13B
PE Ratio (TTM)22.81
Earnings DateN/A
Dividend & Yield3.35 (3.75%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Will Sanofi (SNY) Prove to be a Suitable Value Stock?
    Zacks19 hours ago

    Will Sanofi (SNY) Prove to be a Suitable Value Stock?

    Value investing is easily one of the most popular ways to find great stocks in any market environment.

  • PR Newswire22 hours ago

    Sanofi Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities Nationwide to Help Improve Patient Outcomes through Peer-to-Peer Education

    CAMBRIDGE, Mass., March 22, 2017 /PRNewswire/ -- Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the extension of the Multiple Myeloma Journey Partners Program that leverages storytelling as a tool to improve the patient experience with multiple myeloma. Journey Partners are multiple myeloma patients that have experienced similar emotions, faced the same challenges and asked the same questions about living with the disease. "Sanofi Genzyme created the Multiple Myeloma Journey Partners Program to let multiple myeloma patients know they are not alone and to provide educational resources and services that help patients and families navigate their journey to achieve the best possible outcomes," says Bhavesh Ashar, Vice President and General Manager of US Oncology, Sanofi Genzyme.

  • American City Business Journals2 days ago

    Sanofi-Genzyme files preemptive legal strike to protect eczema drug

    Sanofi-Genzyme, which expects to soon win approval for an eczema drug, has filed a federal lawsuit that seeks to preempt a possible patent challenge by Amgen. The Cambridge-based firm, a unit of French pharmaceutical giant Sanofi SA (SNY), filed a suit in Boston federal court along with its partner Regeneron Pharmaceuticals (REGN). The complaint asks a judge to rule that the drug does not infringe a patent held by Amgen (AMGN).